LeonaBio
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
18706 North Creek Pkwy Ste 104, Bothell,...Website
www.leonabio.comRevenue
<$5 MillionIndustry
About LeonaBio
LeonaBio Org Chart
Is LeonaBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at LeonaBio
Click to see if LeonaBio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if LeonaBio is spiking on competitors!
Earning: See what the market has to say on LeonaBio recently announced quarterly report
Funding: Get notified immidiatlly once LeonaBio has new funding data
Check if LeonaBio has recently received funding, and reach out quickly before it becomes old news!
LeonaBio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when LeonaBio launches new products
Recommended Actions
Reach out to Masked Content who joined LeonaBio as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
LeonaBio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
LeonaBio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about LeonaBio.
LeonaBio Tech Stack
A closer look at the technologies used by LeonaBio
Most Recent Scoops
LeonaBio News & Media
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
On Track to Complete Enrollment of the Phase 3 ELAINE-3 clinical trial in 4Q 2026 with Topline Data Expected in 2H 2027 On Track to Complete Enrollment of the Phase 3 ELAINE-3 clinical trial in 4Q 2026 with Topline Data Expected in 2H 2027LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
Introduces brelgometon as the International Nonproprietary Name (INN) for ATH-1105 Introduces brelgometon as the International Nonproprietary Name (INN) for ATH-1105LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding LeonaBio
LeonaBio, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics, including small-molecule drug candidates for treatment-resistant metastatic breast cancer, amyotrophic lateral sclerosis (ALS), and other serious conditions. It was previously known as Athira Pharma, Inc. and recently rebranded to LeonaBio to... Read More